MedTrace Logo

Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial

NCT02432885 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2015-05-04

No results posted yet for this study

Summary

This trial intends to evaluate myocardial Fibrosis progression in Duchenne and Becker Muscular Dystrophy, as well the influence of ACE inhibitors in fibrosis progression. Additionally, this study aims to determine genetic predictors of cardiac involvement in these dystrophies.

Conditions

  • Myocardial Fibrosis
  • Muscular Dystrophies

Interventions

DRUG

Enalapril

up to 20mg bid

Sponsors & Collaborators

  • Federal University of Minas Gerais

    collaborator OTHER

  • University of Sao Paulo

    collaborator OTHER

  • InCor Heart Institute

    lead OTHER

Principal Investigators

  • Carlos E Rochitte, MD, PhD · InCor, Heart Institute, University of Sao Paulo Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-06-30
Completion
2013-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432885 on ClinicalTrials.gov